Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-meso in Metastatic Pancreatic Cancer
NCT03638193Phase 1Unknown
- Sponsor
- BinDeBio
- Start
- Jul 2018
- Primary completion
- Feb 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART-meso cells in pancreatic cancer (PC) (2 cohorts), sponsored by BinDeBio. Primary endpoint: Safety of CART-meso infusion: number of adverse events at 60 months. Status: unknown.
02
Drugs
CART-meso cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03638193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638193.